ACIP Greenlights Critical Vaccines from Pfizer and GSK

In a groundbreaking move, the CDC’s Advisory Committee on Immunization Practices (ACIP) has formally endorsed expanded usage for Pfizer’s Abrysvo, aimed at protecting against respiratory syncytial virus (RSV), and GSK’s newly approved Penmenvy, a pioneering 5-in-1 meningococcal vaccine.

RSV Vaccine Recommendations Expanded for Older Adults

ACIP has opted to widen the recommendation for RSV vaccinations, including individuals aged 50 to 59 who have an increased risk of severe RSV-related respiratory issues. This important decision comes on the heels of the FDA’s October 2024 approval of Abrysvo for adults aged 18 to 59 at higher risk.

"This expanded adult RSV vaccination recommendation is a crucial step towards safeguarding those aged 50 to 59 who face severe illness due to underlying conditions," stated Alejandro Cane, Pfizer’s VP of vaccines and antivirals. With Abrysvo’s breadth of indication, it now serves not only older adults and at-risk individuals but also pregnant women to protect their infants.

RSV: A Global Health Threat

According to the World Health Organization, RSV is responsible for about 3.6 million hospitalizations and around 100,000 deaths annually among children worldwide. In the U.S. alone, it is estimated to cause 160,000 hospitalizations and 10,000 deaths each year among seniors over 65, particularly impacting those with chronic health conditions.

GSK's 5-in-1 Meningococcal Vaccine: A Game Changer

In a parallel announcement, ACIP has recommended GSK's Penmenvy as a viable alternative to individual meningococcal group ACWY and MenB vaccinations for patients over 10. This innovative vaccine merges components from GSK’s established Bexsero and Menveo vaccines, offering comprehensive protection against five major meningococcal serogroups (A, B, C, W, and Y) with a single injection.

This strategic recommendation aims to simplify vaccine administration and confront the persistently low vaccination rates for MenB, which sits at around a concerning 13% among U.S. adolescents.

A Rising Threat: Meningococcal Disease

Recent CDC data reveals a troubling increase in meningococcal cases across the United States, surpassing pre-pandemic levels. In 2023, 438 cases were reported—the highest since 2013. The disease disproportionately affects individuals aged 30 to 60, particularly Black individuals and those living with HIV, with a mortality rate as high as 18% within the last year.

Tony Wood, GSK's Chief Scientific Officer, expressed enthusiasm for this recommendation: "This positive endorsement can significantly enhance disease prevention efforts across the U.S., especially among adolescents and young adults who are at elevated risk. The pentavalent vaccine strategy will help improve immunization uptake while streamlining administration."